A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.
A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.
复制标题
DOI：
10.1186/1472-6890-13-5
复制
发表时间：
2013-02-06
影响因子：
--
通讯作者：
Matsubara O
中科院分区：
文献类型：
--
作者：
Kobayashi T;Iwaya K;Moriya T;Yamasaki T;Tsuda H;Yamamoto J;Matsubara O
Ki 67被广泛用于区分管腔型乳腺癌的“A”和“B”亚型。本研究旨在验证p53与Ki 67结合对乳腺癌的预后价值。对150例激素受体（HR）阳性的癌组织进行Ki 67、p53和分子标志物HER 2、CK 5/6、CK 14、EGFR、FOXA 1、GATA 3和P-钙粘蛋白的免疫染色检查。将包含Ki 67和p53的免疫组化面板的预后价值与单个Ki 67标记指数（LI）的预后价值进行比较，并进行单因素和多因素分析。根据免疫组化结果将患者分为有利表型组（低Ki 67 LI，p53阴性）和不利表型组（高Ki 67 LI和/或p53阳性），产生了明显不同的无病生存（P<0.0001）和总生存（P=0.0007）的Kaplan-Meier曲线。这些差异比相应的低Ki 67 LI与高Ki 67 LI曲线之间的差异明显得多。虽然其他分子标志物的预后价值并不显著，但多变量分析显示Ki 67-p53联合状态是一个独立的预后因素。这些数据表明，包括Ki 67和p53的免疫组化面板是管理HR阳性乳腺癌患者的实用工具。
Ki67 is widely used in order to distinguish the “A” and “B” subtypes of luminal-type breast cancer. This study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer. Immunostaining for Ki67, p53, and the molecular markers HER2, CK5/6, CK14, EGFR, FOXA1, GATA3, and P-cadherin was examined hormone receptor (HR)-positive cancer tissues from 150 patients. The prognostic value of an immunohistochemical panel comprising Ki67 and p53 was compared with that of the single Ki67 labeling index (LI), and uni- and multivariate analyses were performed. Division of the patients based on the immunohistochemistry results into favorable- (low Ki67 LI, p53-negative) and unfavorable- (high Ki67 LI and/or p53-positive) phenotype groups yielded distinctly different Kaplan-Meier's curves of both disease-free (P<0.0001) and overall survival (P=0.0007). These differences were much more distinct than those between the corresponding low Ki67 LI vs. high Ki67LI curves. While the prognostic values of the other molecular markers were not significant, combined Ki67-p53 status was an independent prognostic factor by multivariate analysis. These data indicate that an immunohistochemical panel comprising Ki67 and p53 is a practical tool for management of patients with HR-positive breast cancer.